The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux.
In April, the FDA said it had nailed one of the key players bringing counterfeit Avastin into the U.S. and wanted to make an example of him with federal jail time. But a judge in Montana has sentenced him to house arrest instead.
Roche nabbed a first-line approval for Avastin in brain cancer. Japanese regulators cleared the drug to treat aggressive brain tumors, including newly diagnosed glioblastoma, as monotherapy and in combination with radiation and chemo.
Here's a roundup of news on approved drugs from this year's American Society of Clinical Oncology conference, comprising highlights from FierceBiotech 's weekend coverage as well as recent releases.
Roche took two steps forward and one step back on the Avastin front today, as investigators laid out a clear advantage in adding the therapy to chemo for cervical cancer while finding no survival advantage when adding it to first-line treatment of an aggressive form of brain cancer.
The FDA and U.S. law enforcement are continuing their crackdown on Internet sales of illegally imported drugs, even enlisting the help of Interpol and police in London and Germany to track and arrest two Pakistani men accused of selling controlled substances online.
The U.K.'s cost-effectiveness police have been arresting Roche's Avastin development efforts once again. As Cover magazine reports, the National Institute for Health and Clinical Excellence has nixed two proposed uses for the drug in ovarian cancer, one of the hardest-to-treat forms of the disease.
One of the key players in an investigation of counterfeit Avastin that appeared to have been imported into the U.S. by a Canadian Internet pharmacy has pleaded guilty to playing a part in the operation.
Regulators have again turned down Roche's cancer drug Avastin for payment by the National Health System (NHS), this time for use on a recurrent, advanced ovarian cancer. But that doesn't mean patients won't get it.
The effects of a nasty flu season may wear off quickly, but two newly launched breast cancer drugs should help to keep the oncology increases coming.